 Monoclonal antibodies that inhibit the epidermal growth factor and vascular endothelial growth factor pathways are showing great therapeutic benefit in the treatment of metastatic colorectal cancer (mCRC). Medical and community oncologists, oncology nurses, and primary care physicians who treat patients with mCRC need ongoing education regarding these antibodies and their use in mCRC treatment. You must be aware of new data on first-line, second-line, and combination therapies and the impact of these treatments on patient outcomes and overall survival. Through online case-directed workshops and interactive monitors, you will learn about current efficacy and safety data for targeted therapies, as well as their use in clinical practice.
|
 The mCRC Monitor is an interactive newspaper designed to keep you up-to-date on issues and concerns surrounding mCRC. 
Issue 1:The Current mCRC Landscape |
|
|
|
